Blood Based Biomarkers Market Size & Growth Forecast 2027–2036, By Segments (End Use, Type, Application, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Blood Based Biomarkers Market size was worth USD 9.3 billion in 2026 and is expected to grow at a 7.03% CAGR between 2027 and 2036, reaching USD 18.35 billion by 2036. The industry revenue for 2027 is assessed at USD 9.85 billion.
Get more details on this report
Request Free Sample ReportBlood Based Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 45.35% share, driven by advanced clinical testing infrastructure, precision medicine adoption, and strong integration of biomarker diagnostics across oncology, neurology, and cardiovascular care.
- Asia Pacific expands at 8.25% CAGR, supported by rising diagnostic demand, expanding healthcare access, and growing adoption of scalable blood-based testing across large patient populations.
Segment Momentum
- Hospitals & Clinics held a 49.72% share in 2026 because biomarker testing is integrated into routine diagnosis, disease monitoring, and physician-led treatment planning, supported by high patient volumes and established care pathways.
- Diagnostic laboratories are expanding rapidly as demand grows for specialized testing, efficient sample processing, broader test menus, and scalable workflows that support increasing biomarker-based screening and monitoring requirements.
Market Expansion Drivers
- Rising prevalence of cardiovascular and chronic diseases increasing demand for early diagnostic biomarkers.
- Advancements in NGS and liquid biopsy technologies improving non-invasive disease detection accuracy.
- Expanding pharmaceutical investment in precision medicine accelerating biomarker-driven therapeutic development.
Leading Market Participants
- Major companies in the blood based biomarkers market include Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (United States), bioMérieux SA (France), Bio-Rad Laboratories Inc. (United States), Sysmex Corporation (Japan), Danaher Corporation (United States), QuidelOrtho Corporation (United States), Illumina Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 9.3 billion
- 2027 Estimated Market Size: USD 9.85 billion.
- Projected Market Size: USD 18.35 billion by 2036
- Growth Forecast: 7.03% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hospitals & Clinics (End Use) | Genetic Biomarkers (Type) | Cancer (Application) | Next-Generation Sequencing (Technology)
- Emerging Opportunity Segment: Diagnostic Laboratories (End Use) | Cell-Based Biomarkers (Type) | Neurological Diseases (Application) | Polymerase Chain Reaction (Technology)
Market Growth Drivers and Industry Trends
Rising prevalence of cardiovascular and chronic diseases increasing demand for early diagnostic biomarkers
The expanding burden of cardiovascular conditions and other chronic diseases is increasing the need for earlier and more accessible disease identification, providing a significant foundation for the blood based biomarkers market. Blood-based testing can enable clinicians to assess biological indicators associated with disease development, progression, and treatment response without relying exclusively on invasive diagnostic procedures. As healthcare systems place greater emphasis on early detection, risk assessment, and ongoing disease monitoring, the use of biomarkers in routine and specialized diagnostic pathways is becoming increasingly relevant for managing patients with chronic conditions.
Advancements in NGS and liquid biopsy technologies improving non-invasive disease detection accuracy
Technological progress in next-generation sequencing and liquid biopsy is improving the ability to identify disease-associated molecular signals from blood samples, creating new applications for biomarker-based diagnostics. The blood based biomarkers market is supported by these advances because improved analytical sensitivity and molecular characterization can facilitate non-invasive detection and monitoring of diseases. Liquid biopsy approaches can provide access to circulating biological information through blood collection, while NGS technologies enable detailed analysis of molecular changes, supporting the development of more precise diagnostic and monitoring strategies.
Expanding pharmaceutical investment in precision medicine accelerating biomarker-driven therapeutic development
Pharmaceutical companies are increasingly integrating biomarker information into drug discovery, clinical development, patient selection, and treatment monitoring, strengthening demand for reliable biological indicators. This trend will accelerate the blood based biomarkers market as precision medicine approaches require measurable signals to help identify suitable patient populations and evaluate therapeutic responses. Biomarker-driven development can also support the differentiation of disease subgroups and improve understanding of treatment outcomes, encouraging greater use of blood-based testing throughout pharmaceutical research and the development of targeted therapies.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of cardiovascular and chronic diseases increasing demand for early diagnostic biomarkers | 2.00% | High | North America, Europe | High | Near Term |
| Advancements in NGS and liquid biopsy technologies improving non-invasive disease detection accuracy | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Expanding pharmaceutical investment in precision medicine accelerating biomarker-driven therapeutic development | 1.50% | Moderate | Europe, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the blood based biomarkers market, North America held the largest share of 45.35% in 2026, reflecting advanced healthcare infrastructure, strong diagnostic capabilities, and substantial adoption of biomarker-based approaches in clinical research and disease management. Growing interest in minimally invasive diagnostic methods is supporting the use of blood-based biomarkers for disease detection, monitoring, prognosis, and treatment selection. The region's established life sciences ecosystem and integration of advanced molecular diagnostics into healthcare are further strengthening demand. Increasing focus on personalized medicine and early disease identification is also encouraging the development and clinical application of blood-based biomarker technologies.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to be the fastest-growing region, driven by expanding healthcare access, rising investment in diagnostic infrastructure, and growing awareness of early disease detection. Increasing prevalence of chronic and complex diseases is encouraging healthcare systems to improve diagnostic capabilities and adopt more efficient approaches to disease monitoring. Advances in molecular testing, precision medicine, and laboratory technologies are broadening the potential applications of blood-based biomarkers across clinical settings. At the same time, healthcare modernization and expanding research activity are creating a stronger environment for biomarker development, validation, and adoption throughout the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Diagnostics FocusGermany advances blood based biomarkers through translational research and clinical laboratory integration. The market emphasizes standardized validation processes, reliable diagnostic performance, and adoption within healthcare systems seeking earlier disease identification and personalized treatment decisions.
France 🇫🇷
Preventive Care ApplicationsFrance encourages the adoption of blood based biomarkers to strengthen preventive healthcare and disease monitoring. Research organizations and healthcare providers focus on clinically relevant biomarkers that support earlier diagnosis and improved treatment planning in routine medical practice.
Italy 🇮🇹
Clinical Laboratory AdoptionItaly expands blood based biomarker utilization through hospital laboratories and diagnostic service providers seeking improved clinical decision-making. Market priorities include validated testing workflows, practical implementation, and collaboration between research institutions and healthcare networks.
Japan 🇯🇵
Precision Diagnostic IntegrationJapan focuses on incorporating blood based biomarkers into precision diagnostics for oncology, neurology, and chronic disease management. Healthcare providers prioritize clinically validated biomarkers that improve routine testing efficiency while supporting individualized patient care strategies.
South Korea 🇰🇷
Molecular Testing ExpansionSouth Korea strengthens the blood based biomarkers market through investments in molecular diagnostics and advanced laboratory capabilities. Clinical institutions emphasize rapid assay development, data-driven diagnostics, and integration with precision healthcare programs across multiple therapeutic areas.
United States 🇺🇸
Clinical Innovation PipelineThe U.S. blood based biomarkers market is driven by strong clinical research, precision medicine initiatives, and expanding diagnostic applications. Healthcare organizations prioritize biomarker validation, integration with advanced laboratory platforms, and collaboration between biotechnology developers and healthcare providers.
Segment Leadership and Growth Trends
Blood Based Biomarkers Market Share (%), by End Use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd Use Segment Analysis: Hospitals & Clinics (Largest Segment) vs Diagnostic Laboratories (Fastest-Growing Segment)
Hospitals & clinics held the largest share of the blood based biomarkers market in 2026, accounting for 49.72% share, supported by their central role in disease diagnosis, treatment planning, patient monitoring, and clinical decision-making. The availability of integrated diagnostic infrastructure and access to diverse patient populations enables hospitals and clinics to incorporate blood-based biomarkers across multiple stages of care. Growing emphasis on earlier disease detection and personalized treatment is further reinforcing the use of biomarker-based testing in routine and specialized clinical settings.
Diagnostic laboratories represent the fastest-growing end-use segment as testing becomes increasingly specialized and dependent on advanced analytical capabilities. These facilities provide dedicated environments for high-throughput biomarker analysis, enabling healthcare providers to access detailed diagnostic information without requiring all testing capabilities within clinical facilities. Increasing demand for precision diagnostics, decentralized testing support, and more efficient laboratory workflows is strengthening the role of diagnostic laboratories in biomarker analysis.
Type Segment Analysis: Genetic Biomarkers (Largest Segment) vs Cell-Based Biomarkers (Fastest-Growing Segment)
Genetic biomarkers led the blood based biomarkers market in 2026, with a 35.98% share, reflecting their importance in identifying inherited characteristics, disease-associated genetic changes, and molecular indicators relevant to diagnosis and treatment selection. Advances in genomic analysis and the expanding use of precision medicine are increasing the clinical value of genetic information obtained through blood samples. Their applicability across oncology, hereditary disorders, and other disease areas continues to support broad utilization.
Cell-Based biomarkers are expanding rapidly as improvements in cellular analysis enable more detailed assessment of disease biology and treatment response. These biomarkers can provide information on immune activity, circulating tumor cells, and other cellular characteristics that may not be captured through conventional molecular measurements alone. Growing interest in personalized healthcare, immunological assessment, and advanced disease monitoring is encouraging wider adoption of cell-based approaches.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End Use | Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others | Hospitals & Clinics | Diagnostic Laboratories |
| Type | Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers | Genetic Biomarkers | Cell-Based Biomarkers |
| Application | Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Others | Cancer | Neurological Diseases |
| Technology | Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Others | Next-Generation Sequencing | Polymerase Chain Reaction |
Competitive Landscape and Market Positioning
Top players in the blood based biomarkers market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche AG (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Thermo Fisher Scientific Inc. (United States)
5. bioMérieux SA (France)
6. Bio-Rad Laboratories Inc. (United States)
7. Sysmex Corporation (Japan)
8. Danaher Corporation (United States)
9. QuidelOrtho Corporation (United States)
10. Illumina Inc. (United States)
Advancements in precision medicine and non-invasive diagnostics are accelerating activity within the blood based biomarkers market. Developers are integrating AI-enabled analytics and molecular testing platforms to improve disease detection accuracy and personalized treatment planning. Continuous research into novel biomarker identification and liquid biopsy technologies is also strengthening clinical adoption across oncology, neurology, and chronic disease management applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche AG (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Sysmex Corporation (Japan) | |||||||
| Danaher Corporation (United States) | |||||||
| QuidelOrtho Corporation (United States) | |||||||
| Illumina Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Metabolic | May-26 | Metabolic has integrated Roche’s plasma p-Tau217 blood test into its healthcare service offerings to target early Alzheimer’s detection in high-risk patient populations. This initiative marks a significant advancement in routine clinical screening, utilizing high-sensitivity diagnostic assays to transition from specialized research settings into broader, metabolically-focused patient care pathways for neurodegenerative disease monitoring. |
| Neurophet | May-26 | Neurophet is expanding its operational reach through new pharmaceutical collaborations and multiple U.S. hospital pilot projects focused on Alzheimer’s disease. The company is actively positioning its AI-driven neuroimaging and biomarker solutions for commercial scale-up, addressing the growing demand for integrated diagnostic support tools that facilitate early detection and clinical management of neurodegenerative conditions. |
| Alzheimer's Drug Discovery Foundation | Mar-26 | The Alzheimer's Drug Discovery Foundation launched a $50 million Diagnostics Accelerator initiative focused on advancing blood-based biomarkers. By targeting tau-related blood tests and AI-enabled diagnostic platforms, the program aims to bridge the gap between emerging biomarker research and clinical implementation, supporting precision medicine initiatives and accelerating the commercialization of non-invasive neurodegenerative disease detection tools. |
| Circular Genomics | Dec-25 | Circular Genomics secured $15 million in Series A funding to expedite the clinical validation and commercialization of its circular RNA-based biomarker platform. The investment provides the necessary capital to scale its proprietary diagnostic technology and strengthen its competitive standing in the development of next-generation, high-accuracy blood-based screening solutions for early Alzheimer’s disease detection. |
| Quest Diagnostics | Oct-25 | Quest Diagnostics validated that two of its proprietary blood-based biomarker tests for Alzheimer’s disease meet stringent clinical guideline-based accuracy thresholds. This technical confirmation enhances clinical confidence in blood-based diagnostic pathways, supporting the transition toward non-invasive testing protocols as a standard of care for confirming Alzheimer’s pathology in routine clinical and primary care settings. |
| Labcorp | Aug-25 | Labcorp successfully launched the first FDA-cleared blood test for Alzheimer’s disease in the United States. This regulatory milestone provides a critical pathway for more accessible, early-stage diagnostics, facilitating broader clinical adoption of biomarker-driven care models and enhancing decision-making processes for patients and healthcare providers across the country. |
| FYR | Apr-25 | FYR has initiated a collaboration with the Mayo Clinic to leverage an extracellular vesicle-based AI platform for identifying novel blood-based biomarkers associated with Parkinson’s disease. This research-focused partnership aims to enhance the discovery and development of advanced diagnostic tools, ultimately improving early identification capabilities and enabling more effective therapeutic monitoring for complex neurodegenerative disorders. |
| Quanterix Corporation | Jan-25 | Quanterix Corporation entered a definitive merger agreement to acquire Akoya Biosciences. This integration combines specialized capabilities in ultra-sensitive detection for blood- and tissue-based protein biomarkers. The strategic move is designed to accelerate biomarker translation workflows, consolidate market positioning in proteomics, and realize operational cost synergies while expanding the combined entity's customer footprint. |
| Biogen Inc. | Jul-24 | Biogen Inc., in collaboration with Beckman Coulter and Fujirebio, established a strategic partnership to develop minimally invasive, blood-based biomarkers specific to tau pathology in Alzheimer’s disease. This alliance focuses on creating novel diagnostic tools capable of stratifying patients and monitoring therapeutic responses, addressing a critical need for standardized, scalable diagnostics in the neurodegenerative treatment pipeline. |
| Cleveland Diagnostics, Inc. | Jan-24 | Cleveland Diagnostics raised over $75 million in growth capital, led by Novo Holdings, to accelerate the development of its non-invasive, blood-based diagnostic portfolio. The funding supports the expansion of the company’s platform, including the IsoPSA prostate cancer test, aimed at improving diagnostic accuracy, reducing rates of clinical overdiagnosis, and streamlining early-detection workflows in oncology. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Blood Based Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Stage | Screening & Risk Assessment, Early-Stage Diagnosis, Disease Monitoring, Treatment Response & Recurrence Monitoring, Advanced Disease Assessment |
| Clinical Purpose | Diagnostic Testing, Prognostic Testing, Predictive Testing, Disease Monitoring, Treatment Selection & Monitoring |
| Biomarker Development Stage | Discovery & Research, Clinical Validation, Clinical Diagnostic Use, Commercialized Routine Testing |
Blood Based Biomarkers Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Pathways and Diagnostic Workflow Integration |
|
| Precision Medicine and Companion Diagnostics Expansion |
|
| Reimbursement, Market Access, and Commercialization |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the blood based biomarkers market?
What are the growth projections for the blood based biomarkers industry?
How is rising chronic disease prevalence influencing adoption of blood-based biomarkers in early diagnosis?
How are NGS and liquid biopsy advancements reshaping clinical adoption of blood-based biomarkers?
Why do hospitals and clinics lead the blood based biomarkers market?
Why are diagnostic laboratories the fastest-growing end-use segment in the blood based biomarkers market?
Why does North America dominate the blood based biomarkers market?
How is Asia Pacific driving growth in blood based biomarkers?
Who are the leading players in the blood based biomarkers landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization